About NeuroEM

Our mission

At NeuroEM Therapeutics®, our mission is to revolutionize the drug-free treatment of cognitive decline through our groundbreaking Transcranial Electromagnetic Treatment, leveraging Radio Frequencies (TEMT-RF) technology. We are dedicated to translating over a decade of rigorous clinical research to develop safe, effective, and non-invasive solutions that stop and even reverse cognitive deterioration, offering hope to millions affected by neurodegenerative diseases like Alzheimer’s and those striving to maintain cognitive health throughout the aging process.

First-in-class device designed to fight Alzheimer’s

NeuroEM Therapeutics’ “first-in-class” MemorEM™ device was designed to be comfortably worn on the head to administer TEMT-RF during daily in-home treatment.

Our pioneering TEMT-RF technology has shown extraordinary promise against Alzheimer’s in all completed preclinical and clinical studies.

The electromagnetic waves emanating from multiple emitters in the wearable head cap disaggregate toxic protein ‘oligomers’ within neurons throughout the brain. Since these oligomers are increasingly believed to be the root cause of Alzheimer’s disease, we believe the MemorEM head device will directly attack the Alzheimer’s disease process.

TEMT-RF has two additional mechanisms of action that attack Alzheimer’s and other causes of cognitive decline – TEMT-RF re-balances the immune system in both brain and blood and TEMT-RF increases the energy production of brain cells.

NeuroEM’s MemorEM device will be available through neurologists and other health professionals who diagnose memory disorders once we complete our pivotal trials and receive FDA approval.

Read the NeuroEM Story

Leadership Team

Chuck Papageorgiou

Chief Executive Officer

LinkedIn
Tracy Ingram

Chief Operating
& Information Officer

LinkedIn
Amanda Patanow

Chief Product
& Marketing Officer

LinkedIn
Marilyn Thompson

Chief Financial Officer

LinkedIn
Edward Goodwin, Ph.D.

Chief Scientist

LinkedIn
Chuanhai Cao, MPH, Ph.D.

Head of USF Research Team

LinkedIn
Rob Baranowski

Sr. Engineer
Product Development

LinkedIn
Patty Meagher

Community Advocate

LinkedIn

Directors & Advisors

Gary Arendash, PhD
Founder & Scientist Emeritus

Dr. Arendash served as a Full Professor and Research Professor at the University of South Florida for 30 years. During his final six years there, he directed the Florida Alzheimer’s Disease Research Center’s Animal Core and one of its three principal research initiatives. Specializing in the development of Alzheimer's disease therapeutics, Dr. Arendash has published over 120 peer-reviewed articles in first-tier journals, such as Science, Nature, and the Journal of Alzheimer’s Disease, where he served as Senior Editor until 2017. During his tenure at USF, he secured $5 million in research funding from external agencies, including the National Institutes of Health (NIH) and the Alzheimer’s Disease and Related Disorders Association (ADRDA). Dr. Arendash was among the pioneers to demonstrate that Alzheimer's Disease begins in the brain decades before its clinical diagnosis. His landmark study in 2010 provided initial evidence that electromagnetic treatment induces cognitive benefits in Alzheimer's mice through multiple disease-modifying mechanisms. He further advanced this promising pre-clinical research by conducting three clinical studies from 2019 to 2023, which demonstrated the safety and efficacy of the technology he developed against Alzheimer’s. Dr. Arendash received his doctorate in Neuroscience/Physiology from the University of California, San Francisco (UCSF) and completed his post-doctoral research at UCLA’s Brain Research Institute before joining the University of South Florida faculty.

William Scott Burgin, MD
Medical Advisor

Dr. Burgin, a professor of neurology and stroke division chief at the University of South Florida, brings a wealth of expertise to the field of neurology, including clinical care, research, administration, and teaching. His extensive background includes a deep focus on stroke-related artificial intelligence (AI), biomarkers, and intellectual property (IP) development. Throughout his distinguished career, Dr. Burgin has made significant contributions to the medical community, evidenced by his authorship of over 100 peer-reviewed articles and active contributions to more than 75 clinical research projects.

Dr. Burgin is passionate about leveraging innovative technologies to enhance patient outcomes. In addition to his role on the NeuroEM medical advisory board, he currently serves as the Chief Medical Advisor for a biotechnology company in Tampa. He has also co-founded two pioneering companies in the Tampa Bay region. One focuses on novel neuroprotectant approaches, exploring new methods to safeguard and restore neural function. The other harnesses the power of AI to assist stroke patients with communication disorders, fostering improved communication and increased independence.

By combining his academic prowess with his entrepreneurial spirit, Dr. Burgin continues to make a lasting impact on the neurological community and beyond.

Jonathan Gordon
Chairman of the Board

Jon Gordon is a co-founder and managing partner of Stage One Ventures an early-stage venture capital firm, founded in 2006. He has been a successful executive, entrepreneur, and investor for over 30 years. He has been at the forefront of many historic market and technological changes in the high-tech global economy. Jon led Investments in e-Centives (sold to Catalina Marketing), AdelaVoice, Marxent Labs, Maple Farm Media, Carvoyant, Par Elastic, Instream, Veloxum, XPeerient, Delfigo Security, Wing Power, Phantom Alert, OnePin, Cuesol (sold to MobileLime), go2 (merged with 80108), SiteWit and Auspice (sold to Arris), SiteWit, and KiteDesk.

Jon is an accomplished executive, entrepreneur, and investor with over 40 years of experience in building technology companies from early and mid-stage to successful exits. His expertise spans enterprise software, system software, semiconductors, and instrumentation industries. Jon is adept at enhancing shareholder value through business development, establishing sales and market channels, ensuring timely product development, and managing operations cost-effectively to achieve profitability. Moreover, he has specialized knowledge in intellectual property monetization and maintains a wide network of high-level global relationships.

Stephen Hull, MHS
Reimbursement Advisor

Stephen Hull is a reimbursement advisor for NeuroEM, specializing in creating integrated market strategies for innovative technologies throughout their entire product lifecycle. Prior to his role as Sr. Vice President of Market Access, Avania, Stephen founded Hull Associates, a global market access and reimbursement strategy firm working in all major therapeutic areas across 22 markets worldwide. A staunch advocate for life-saving innovations, Stephen has dedicated his career to enhancing patient access to life-saving innovations. He has chaired committees for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Stephen holds a Master of Health Sciences degree in Health Policy from the Johns Hopkins Bloomberg School of Public Health and a Bachelor of Arts degree in International Relations, Political Science, and French from Colgate University. Based near Boston, Massachusetts, he is a sought-after speaker for US and international forums on payment systems and the reimbursement of pharmaceuticals, medical devices, and in vitro diagnostics.

Mitch Lairmore, MBA
Director and Proxy for Dr. Arendash

Mitch Lairmore has a strong background in business development, strategic planning, and market research, with extensive experience in the commercialization of technology. He has led product development teams and supported small companies in obtaining SBIR grants from NASA, the US Air Force, and the NSF. As a staff consultant, Mitch provided commercialization assistance to projects funded by the US Navy, the Department of Energy, the National Science Foundation, the Department of Transportation, and the Department of Homeland Security.

Before these roles, he was a subcontractor to a prime contractor for major agencies such as the National Institute of Health, the Department of Energy, and the Environmental Protection Agency. At Eastman Kodak, Mitch served as a business development director, where he was responsible for strategic planning for new products and intellectual property licensing. He co-founded a venture within Kodak’s New Opportunity Development initiative and managed a significant data storage product development effort, securing partnerships and funding.

Mitch was also a board member for a Kodak Ventures Group company, guiding it to profitability. He holds a Certified Global Business Professional certification through the National Association of Small Business International Trade Educators and has assisted small businesses in expanding their international reach. Mitch earned a Master of Business Administration from the William E. Simon Graduate School of Business Administration at the University of Rochester and a Bachelor of Science in Industrial Engineering from the University of Iowa.

Kim H. Manwaring, MD
Medical Advisor

Dr. Manwaring is a board certified pediatric neurosurgeon and inventor of six commercialized devices used throughout the world in various specialties. These include conception of the most widely used intracranial pressure sensor (Codman Microsensor), first approved FDA cranial orthosis (DOCband), Stryker Colorado Microneedle, and the FMwand ferromagnetic energy modality. He holds 25 patents for a variety of surgical tools. He is also a recipient of various awards, including the Physician Achievement Award from the Children's Miracle Network, and is listed in America's Best Doctors. He has lectured in many countries on surgical technique and innovations.

Dr. Manwaring practices pediatric neurosurgery part time at Arnold Palmer Children's Hospital in Orlando. He has also functioned as an adjunct professor of Neuroscience at Brigham Young University. He is CMO of Mu Implant Technologies, LLC. He principally undertakes bench research and prototype design of instruments and transducers, functioning as the Principle Inventor of the FMwand system of Domain Surgical Inc.

Lloyd Marks, MD, MBA, FACC
Medical Advisor

Dr. Marks is a pediatric cardiologist, electrical engineer, inventor and entrepreneur with a Master of Business Administration. He has also earned the designation of Fellow of the American College of Cardiology (FACC), recognizing his outstanding credentials, achievements and contributions to cardiovascular medicine. Renowned for innovation in the medical field, he holds more than 20 medical device patents, most of which have been successfully licensed to industry leaders. As an entrepreneur, Dr. Marks has founded three startup companies, including one that is currently commercializing his medical invention.

He is also a dedicated mentor, guiding student startups, and serves as an adviser to academic institutions, inventors, corporations, and investors. He regularly assists investors conducting due diligence and supports patent attorneys in assessing, protecting, and commercializing medical technology.

Dr. Marks earned his Bachelor of Science in Electrical and Electronics Engineering from the Massachusetts Institute of Technology, his Doctor of Medicine from the University of Michigan Medical School, and a Master of Business Administration for Physician Executives from the University of Tennessee, Knoxville.

Christopher Rumana, MD
Medical Advisor

Dr. Rumana is a neurosurgeon turned health-care strategist with more than two decades of clinical and executive leadership experience. After earning his Bachelor of Arts and Doctor of Medicine degree from Northwestern University, he completed his neurological-surgery residency at Baylor College of Medicine. In 1998, he began practicing in Tallahassee, where he served as President of Tallahassee Neurological Clinic, Chairman of the Division of Neurological Surgery, and later Chief of the Medical Staff at Tallahassee Memorial Hospital, culminating in his election as Chairman of the hospital’s Board of Directors.

Since stepping away from active surgical practice in 2018, Dr. Rumana has focused on advising and investing in innovative healthcare ventures. He is currently Chairman of the Board for two international medical companies and sits on the fiduciary or advisory boards of several others, guiding strategy at the intersection of emerging technology and patient care. At NeuroEM, Dr. Rumana draws on his clinical insight, governance expertise, and deep industry network to help steer breakthrough neuro-technology from concept to clinical impact.

Jamie Rutledge
Director

Jamie is a seasoned technology and development executive who has spent more than two decades turning cutting-edge ideas into market-shifting products across the consumer electronics, industrial goods, and machinery sectors. He brings deep expertise in wireless, integrated circuits, and systems architecture, paired with a proven talent for technology scouting, acquisition, and strategic investment.

Throughout his career, Jamie has led global teams in identifying and integrating external innovations that unlock new growth and drive product value. At Dyson Technology, he oversaw a global research group whose team identified and drove multiple technology intercepts and investments. Earlier, at Lenovo, he was the director of the Systems Innovation Lab in Beijing, China, earning his Senior Staff Membership and kicked off their CVC function in Silicon Valley, work that earned him Lenovo’s Individual Excellence Award for Innovation. As an advisor and Board Member, Jamie leverages his strategic foresight, collaborative leadership style, and vast network of industry relationships to help organizations like NeuroEM harness breakthrough technologies and accelerate their impact.

Johana Carolina Marisol Vega Leonel, PhD
Medical Advisor

Dr. Johana Carolina Marisol Vega Leonel is a multidisciplinary scientist, educator, and strategic advisor with over a decade of experience at the intersection of neuroscience, biomaterials, and translational medicine. Trained in neuroengineering, molecular biology, and polymer science, she has led research on neural network formation, revascularization, and clinical neuroimaging across academic, clinical, and global innovation settings. She holds a doctorate in neuroengineering from the University of Illinois at Urbana-Champaign.

Dr. Vega Leonel conducted postdoctoral research in neurosurgery at Stanford University, where she developed brain-on-a-chip systems, advanced blood-brain barrier drug delivery strategies, and contributed to clinical trials in pediatric glioma imaging. She designed and taught her own accredited course in neuroengineering at Stanford, where she also served as a lecturer in Civic, Liberal, and Global Education, teaching courses in cancer, biology, and public health. Her early research at the CDC focused on biomarker development for national exposure surveillance programs.

She is the Founder and Principal Advisor of Astute Crew LLC, where she consults for academic teams, MedTech startups, and VC-backed ventures on translational strategy, grant development, and global expansion. As the Advisor at Chaanakya Capital and Board Member at the Aquillius Institute, she supports innovation pipelines and commercialization efforts at the intersection of science and entrepreneurship. Her advisory work spans companies across the United States, India, Nigeria, Turkey, Africa, and Slovenia, to name a few, helping accelerate the development of next-generation neurotechnologies worldwide.